A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

• Status: Completed
• Trial end date: 2020-02-10

Summary

This is a phase I study designed to determine the feasibility of transplantation using a novel transplant approach that employs a two-stage haploidentical cell infusion following myeloablative conditioning. This strategy, which includes selective depletion of naïve T cells, may speed immune reconstitution thereby potentially reducing the limitations of traditional haploidentical hematopoietic stem cell transplantation (HSCT) and increasing its potential therapeutic application. Additionally, the investigators intend to explore overall survival, event-free survival, hematopoietic cell recovery and engraftment as well as infection rates and complications in these patients.

• Phase: Phase 1

Details

• Lead Sponsor: St. Jude Children's Research Hospital
• Collaborator: CURE Childhood Cancer, Inc.
• Treatments: Alemtuzumab; Busulfan; Everolimus; Fludarabine; Fludarabine phosphate; Mechlorethamine; Melphalan; Sirolimus